Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eiichi Sasaki has a total of 158 co-authors. Here are the top co-authors by number of shared publications:

  • Katsuhiro Masago

    Pathology and Molecular Diagnostics

    18 shared publications
  • Nobuhiro Hanai

    Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan

    9 shared publications
  • Akari Iwakoshi

    Department of Pathology

    8 shared publications
  • Katsuhiro Masago

    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan

    7 shared publications
  • Shiro Fujita

    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan

    7 shared publications
  • Hiroaki Kuroda

    Department of Thoracic Surgery, Teikyo University Mizonokuchi Hospital, Kanagawa, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan

    6 shared publications

Latest Publications

  • Open Access

    Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy

    by Masafumi Kanno, Chiai Sasaki, Eiichi Kato, Hoshino Terada, Nobuhiro Hanai, Eiichi Sasaki, Mana Fukushima, Toshiki Masuishi, Keisuke Takanari, Yasuto Fukada, et al.

    Background: Nuclear protein in testis (NUT) carcinoma is a rare, aggressive malignancy driven by NUTM1 rearrangement, often misdiagnosed as squamous cell carcinoma, with no established standard therapy. This report describes the clinical course and treatment resistance in primary laryngeal NUT carcinoma and provides insights into potential mechanism‐based therapeutic approaches. Case: A 30‐year‐old man with a laryngeal tumor was initially treated for poorly differentiated squamous cell carcinoma. Recurrent disease prompted re‐evaluation; NUT carcinoma was diagnosed by NUT immunohistochemistry, and the BRD4 :: NUTM1 fusion was confirmed by molecular analysis. A bromodomain and extra‐terminal (BET) inhibitor and alternating vincristine, doxorubicin, and cyclophosphamide (VDC)/ifosfamide and etoposide (IE) chemotherapy induced transient tumor regression, whereas vorinostat, immune checkpoint inhibitors, and other systemic therapies were ineffective. Disease progression was ultimately driven by uncontrolled locoregional recurrence. Autopsy revealed a massive infiltrative tumor with extensive locoregional invasion, whereas distant metastatic disease was limited to minute pulmonary nodules; death resulted from overwhelming infection secondary to uncontrolled locoregional progression rather than systemic metastasis. Conclusion: Early molecular diagnosis and biologically informed multimodal strategies are essential for managing laryngeal NUT carcinoma and overcoming treatment resistance.


  • RNA-seq analysis of nintedanib effects on interstitial pneumonia in preoperative NSCLC patients

    by Hiroaki Kuroda, Katsuhiro Masago, Katsutoshi Seto, Yoshitsugu Horio, Eiichi Sasaki, Shiro Fujita, Hirokazu Matsushita

  • Open Access

    Role of ERβ in Triple-Negative Breast Cancer Associated with p53 and Androgen Receptor

    by Kei Ito, Naoko Honma, Hideaki Ogata, Akimitsu Yamada, Mika Miyashita, Tomio Arai, Eiichi Sasaki, Kazutoshi Shibuya, Tetuo Mikami, Masataka Sawaki

    In triple-negative breast cancer (TNBC), the clinicopathological significance of the expression of a second estrogen receptor, ERβ, remains unclear. Further, although the clinicopathological significance of mutant p53 and androgen receptor (AR) has been investigated in TNBC, they have not been established as therapeutic targets. Experimental studies reported the importance of cross-talk between ERβ and p53 or AR in TNBC. In this study, we immunohistochemically examined ERβ expression in surgical specimens of TNBC obtained from postmenopausal patients who underwent surgery without neoadjuvant therapy and investigated the relationship between ERβ expression and various clinicopathological factors, including clinical outcome, while also considering p53 and AR. No significant difference in clinical outcome was noted according to the ERβ status alone (p = 0.2908). However, the ERβ status did affect the relationship between the clinical outcome and p53 or AR status; p53-positive or AR-positive group exhibited significantly more favorable clinical outcomes than p53-negative or AR-negative group, respectively, in the ERβ-positive group (p53, p = 0.0265; AR, p = 0.0285), but not in the ERβ-negative group (p53, p = 0.7228; AR, p = 0.7734). This may be the result of a functional interaction between ERβ and p53 or AR. The role of ERβ in TNBC will be elucidated in further complex studies considering multiple molecules.

  • Aerogenous Dissemination of DEK::AFF2 Carcinoma

    by Eiichi Sasaki, Jen-Fan Hang, Yoshitsugu Horio, Akari Iwakoshi, Katsuhiro Masago, Masahide Oki

    In this article, we describe a previously underrecognized pattern of aerogenous dissemination to the lungs, based on 2 cases of sinonasal DEK::AFF2 carcinoma. Over follow-up periods of 10 and 18 years, respectively, both patients exhibited recurrent multiple endotracheal and endobronchial metastases. These lesions were successfully managed with endoscopic tumor resection. No lymph node involvement or distant metastases beyond the trachea and bronchi were observed; they were entirely absent in one case and largely absent in the other. Based on these clinical courses, the tracheobronchial dissemination was most plausibly interpreted as aerogenous rather than lymphatic or hematogenous spread. DEK::AFF2 carcinoma appears to exhibit three key biological features favoring aerogenous dissemination: anatomic location of the primary tumor, loss of intercellular adhesion, and strong affinity for ciliated respiratory epithelium. These cases may help enhance our understanding of aerogenous tumor cell spread, including phenomena such as spread through air spaces (STAS).


  • S100-positive stroma in salivary gland basal cell adenoma: recent progress and future perspectives

    by Eiichi Sasaki, Katsuhiro Masago, Yasuko Fujita

    Basal cell adenoma (BCA) with S100-positive stroma exhibits tricellular differentiation, consisting of bilayered epithelial cells and S100-positive spindle-shaped stromal cells. While the neoplastic nature of the stromal component has been supported by multiple lines of evidence, its myoepithelial origin, suggested by ultrastructural analysis, has not yet been confirmed by other methodological approaches. This mini-review summarizes the key findings of ultrastructural, immunohistochemical and molecular studies with a particular emphasis on the biological nature of the stromal component. Elucidating the lineage and molecular profile of this unique stroma may contribute to a more refined classification and enhance our understanding of salivary gland tumors.


  • Open Access

    Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes

    by Kazuhiro Toriyama, Katsuhiro Masago, Noriko Shibata, Masataka Haneda, Takamichi Kuwahara, Seiji Natsume, Shota Kobayashi, Yasuko Fujita, Eiichi Sasaki, Kenji Yamao, et al.

    Pancreatic ductal adenocarcinomas (PDACs) with wild‐type KRAS constitute a small fraction of PDACs, and these tumors were recently shown to harbor frequent actionable oncogenic mutations and fusions. However, the clinicopathological features of KRAS wild‐type PDAC have not been well studied. Additionally, precancerous lesions occurring in patients with KRAS wild‐type PDACs have rarely been characterized. Here, we investigated the clinicopathological characteristics and outcomes of 75 patients with KRAS wild‐type PDAC. Molecular analyses were performed in 40 patients using targeted DNA and whole‐exome sequencing and targeted RNA sequencing. We demonstrated that patients with metastatic PDAC with wild‐type KRAS were younger (median 59.5 years) than those with mutated KRAS (median 67 years, p < 0.000055). The wild‐type KRAS status was not a significant prognostic factor for metastatic disease. Molecularly, genes in the RAS pathway are frequently mutated or rearranged (46%, 16/35), including mutations in BRAF, NRAS, HRAS, EGFR, MAP2K1, FGFR1, FGFR3 and ERBB4 and fusions of FGFR2 (FGFR2::CCDC147, FGFR2::CAT, FGFR2::TXLNA), ALK (STRN::ALK, EML4::ALK), and BRAF (TRIP11::BRAF). Mismatch repair deficiency was identified in 10% (4/39) of patients. Potentially actionable alterations were identified frequently in KRAS wild‐type PDACs (30%, 12/40), in which nontubular‐type carcinomas were significantly enriched with actionable alterations compared with tubular adenocarcinomas [67% (6/9) versus 16% (5/31); p = 0.007]. Finally, we investigated the precursors of PDACs in 13 pancreatectomy specimens from patients with KRAS wild‐type PDAC. We identified three pancreatic intraepithelial neoplasias (PanINs) and two intraductal papillary mucinous neoplasms (IPMNs) harboring oncogenic fusions of ALK and BRAF and driver mutations in BRAF and AKT1. This study suggests that in the context of unmutated KRAS, PDAC is driven by alternative oncogenic mutations or fusions of RAS pathway genes, which may be introduced during the early phase of tumorigenesis. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • S100-positive stroma in salivary gland basal cell adenomas: a neoplastic component with CTNNB1 mutations

    by Eiichi Sasaki, Yasuko Fujita, Katsuhiro Masago, Akari Iwakoshi, Nobuhiro Hanai, Hirokazu Matsushita

    Basal cell adenomas (BCAs) are benign epithelial tumors of the salivary gland, characterized by the proliferation of basaloid and luminal cells. In addition, a distinctive spindle cell stroma, that is immunohistochemically-positive for S100, is often observed in BCAs. Based on the ultrastructural findings, the S100-positive stroma was presumed to originate from neoplastic myoepithelial cells. However, immunohistochemical studies do not provide strong evidence supporting a myoepithelial origin, and the true nature of this stroma remains elusive. The aim of this study was to determine whether the S100-positive stroma was neoplastic through a molecular analysis. We selected 2 cases involving BCAs with at least one S100-positive stromal area within the tumor, measuring ≥ 0.2 × 0.2 mm. CTNNB1 I35T mutations were detected in both tumors by Sanger sequencing. Two areas of S100-positive stroma from these two tumors were successfully dissected by manual microdissection using a stereomicroscope without contamination from the surrounding neoplastic bilayered epithelial cells. Because of the small number of dissected stromal cells, the mutation status of these two areas was analyzed using digital PCR, and CTNNB1 I35T mutations were detected in both. In conclusion, this study demonstrated that the S100-positive stroma of BCAs exhibits a neoplastic nature from a molecular perspective. While future studies are needed to confirm whether the S100-positive stroma originates from myoepithelial cells, BCAs morphologically display tricellular differentiation, with neoplastic spindle-shaped stromal cells along with a bilayered neoplastic epithelium.


  • Open Access

    Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report

    by Yutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, Teppei Yamaguchi, Naohiro Watanabe, Junichi Shimizu, Eiichi Sasaki, Yoshitsugu Horio

    Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) are at increased risk of central nervous system (CNS) metastasis at initial diagnosis and throughout treatment. In a phase 3 trial, lorlatinib, a third-generation ALK tyrosine kinase inhibitor, significantly improved progression-free survival. In further analysis, lorlatinib revealed superior intracranial efficacy and prolonged time to intracranial progression compared with crizotinib. Case Presentation: Herein, we report a case of ALK-positive NSCLC with leptomeningeal metastasis that was successfully treated with lorlatinib after progression to brigatinib and alectinib. This case demonstrates the potential of lorlatinib in managing leptomeningeal metastasis in ALK-positive NSCLC. Conclusion: The case suggests a paradigm shift in therapeutic approaches for CNS metastasis, including brain and leptomeningeal metastases.